Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Project ACT

Financiado

Cerrado

Automated autologous cell therapy system

The global burden of cancer, calculated as the cost of years lost from ill-health, disability or early death, currently outweighs all other health concerns including cardiovascular diseases . Among all cancers, metastatic melanoma... ver más

31/03/2017

TPU AS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

TEKNOLOGI PRODUKT UDVIKLING AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-03-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TPU AS

50.00K€ | Lider

Proyectos interesantes

NR2F6-AIM

Medical Technol...

Data Science

Cerrado

CAR-TIME

Medical Technol...

Data Science

1M€ Cerrado

INTHER

Medical Technol...

Data Science

2M€ Cerrado

PDC2022-133865-I00

Medical Technol...

Data Science

127K€ Cerrado

CATCH

Medical Technol...

Data Science

150K€ Cerrado

PowerMiT

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 8 meses Fecha Inicio: 2016-07-24
Fecha Fin: 2017-03-31

Líder del proyecto

TEKNOLOGI PRODUKT UDVIKLING AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The global burden of cancer, calculated as the cost of years lost from ill-health, disability or early death, currently outweighs all other health concerns including cardiovascular diseases . Among all cancers, metastatic melanoma (MM) represents one of the major health problems. Unlike other solid tumors, which mainly affect older adults, MM is notorious for affecting young and middle-aged people, results in 66000 related deaths yearly worldwide (World Health Organization) and therefore has a large impact on years of healthy life lost. Recently, promising results of autologous cell therapy (ACT) with tumour infiltrating lymphocytes (TILs) have shown that up to 20% of patients can be cured with one single course of this immunotherapy . This treatment has been conducted at a handful of institutions with over 1.000 patients treated worldwide. The resulting survival rates of patients treated confirm this approach as being among the most efficient therapies available. Importantly, this novel treatment has the potential to be expanded to the treatment of other cancer types. However, there is a need for dedicated bioreactors for the expansion of TILs for the individual patients. Bioreactors that can provide high cell densities and high absolute cell numbers. Further, TIL production for ACT is labour intensive and must be performed in a sterile cleanroom. This limits the use of this new and efficient cancer treatment to a few highly specialised hospitals. The aim of this application is to develop a dedicated bioreactor that will enable the treatment to be used on an extended number of hospitals. The commercial potential for ACT is estimated to be more than 4 Billion $ per year. . This project is therefore seen as relevant for the topic: Supporting innovative SMEs in the healthcare biotechnology sector - SMEInst-05-2016-2017 Publication date: 14 October 2015.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores